Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMPC in Relapsed/Refractory Acute Myeloid Leukemia
NCT03825146Phase 1Unknown
- Start
- Jan 2019
- Primary completion
- Jan 2021
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of autologous multi-lineage potential cells in acute myeloid leukemia (AML). Primary endpoint: Overall response rate at 12 months. Status: unknown.
02
Drugs
autologous multi-lineage potential cells
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03825146.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03825146.